Robert H. Vonderheide, MD, DPhil
Associate Professor of Medicine
Attending Physician, Hospital of the University of Pennsylvania, Philadelphia, PA
Member, Abramson Cancer Center, University of Pennsylvania School of Medicine
Attending Physician, VA Medical Center, Philadelphia, PA
Associate Investigator, Abramson Family Cancer Research Institute
Program Co-Leader, Immunobiology Program, Abramson Cancer Center, University of Pennsylvania
Associate Cancer Center Director for Translational Research, Abramson Cancer Center, University of Pennsylvania
Department: Medicine
Contact information
8-121 Smilow Center for Translational Research
3400 Civic Center Blvd
Philadelphia, PA 19104
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 215-573-4265
Fax: 215-573-2652
Lab: 215-746-8901
Fax: 215-573-2652
Lab: 215-746-8901
Email:
rhv@exchange.upenn.edu
rhv@exchange.upenn.edu
Graduate Group Affiliations
Publications
Education:
BSc (Chemical Engineering)
University of Notre Dame, 1985.
DPhil (Immunology)
Oxford University, 1989.
MD
Harvard Medical School, 1993.
BSc (Chemical Engineering)
University of Notre Dame, 1985.
DPhil (Immunology)
Oxford University, 1989.
MD
Harvard Medical School, 1993.
Links
Search PubMed for articles
Hematology Oncology Division, Department of Medicine, University of Pennsylania School of Medicine
Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine
Cell and Molecular Biology graduate group, University of Pennsylvania School of Medicine
Search PubMed for articles
Hematology Oncology Division, Department of Medicine, University of Pennsylania School of Medicine
Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine
Cell and Molecular Biology graduate group, University of Pennsylvania School of Medicine
Post-Graduate Training
Intern in Medicine, Massachusetts General Hospital, 1993-1994.
Resident, Internal Medicine, Massachusetts General Hospital, 1994-1996.
Fellow in Hematology/Oncology, Dana-Farber Cancer Institute, 1996-1999.
Intern in Medicine, Massachusetts General Hospital, 1993-1994.
Resident, Internal Medicine, Massachusetts General Hospital, 1994-1996.
Fellow in Hematology/Oncology, Dana-Farber Cancer Institute, 1996-1999.
Certifications
American Board of Internal Medicine (Internal Medicine), 1996.
American Board of Internal Medicine (Medical Oncology), 2000.
American Board of Internal Medicine (Medical Oncology), Recertification 2010-2020, 2010.
Permanent linkAmerican Board of Internal Medicine (Internal Medicine), 1996.
American Board of Internal Medicine (Medical Oncology), 2000.
American Board of Internal Medicine (Medical Oncology), Recertification 2010-2020, 2010.
Description of Clinical Expertise
Medical Oncology and Experimental Therapeutics, in particular ImmunotherapySelected Publications
Vonderheide RH,Burg JM, Mick R, Trosko JA, Li D, Shaik MN, Tolcher AW, Hamid O : Phase I study of CD40 antibody CP-870,893 in combination with carboplatin and paclitaxel in patients with advanced solid tumors OncoImmunology 2: e23033, 2013.Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J, Borghaei H, Kalos M, Vonderheide RH, Albelda SM, June CH, Zhang PJ. : Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Can Res Treat 133: 799-804, 2012.
Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Nasta SD, Goldstein SC, Stadtmauer EA, Smith J, Bailey S, Mick R, Heitjan DF, Emerson SG, Hoxie JA, Vonderheide RH*, Porter DL*. *=shared senior: Effect of blocking lymphocyte chemotaxis on visceral graft-vs-host disease. New England Journal of Medicine 367: 135-145, 2012.
Hardy NM, Fellowes V, Rose JJ, Odom J, Pittaluga S, Steinberg SM, Blacklock-Schuver B, Avila DN, Memon S, Kurlander RJ, Khuu HM, Stetler-Stevenson M, Mena E, Dwyer AJ, Levine BL, June CH, Reshef R, Vonderheide RH, Gress RE, Fowler DH, Hakim FT, Bishop MR. : Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation. Blood 119: 2956-2959, 2012.
Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, Levine BL, Coukos G, Rubin SC, Morgan MA, Vonderheide RH, June CH.: Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Clinical Cancer Research 61: 629-641, 2012.
Doi H, Iyer TK, Carpenter E, Li H, Chang KM, Vonderheide RH, Kaplan DE: Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-Positive B-cell population. Hepatology 55: 709-719, 2012.
Meisel JL, Domchek SM, Vonderheide RH, Giobbie-Hurder A, Lin NU, Winer EP, Partridge AH: Quality of life in long-term survivors of metastatic breast cancer. Clin Breast Cancer 12: 119-126, 2012.
Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell DJ Jr, Colligon TA, Trosko JA, Leinbach LI, Pletcher CH, Tweed CK, DeMichele A, Fox KR, Domchek SM, Riley JL, Vonderheid RH: CD25 blockade depletes and selectively reprograms regulatory T-cells in concert with immunotherapy in cancer patients Science Translational Medicine 4: 134ra62, 2012.
Rhim AD, Mirek ET, Aiello N, Maitra A, Beatty GL, Bailey JM, Reichert M, Vonderheide RH, Leach SD, Stanger BZ : EMT and dissemination precede pancreatic tumor formation. Cell 148: 349-361, 2012.
Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, Vonderheide RH : Tumor-derived granulocyte-macrophage colony stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21: 822-835, 2012.